Nasal levels of soluble IL-33R ST2 and IL-16 in allergic rhinitis: Inverse correlation trends with disease severity

Clinical and Experimental Allergy

Volumn 43, Issue 10, 2013, Pages 1134-1143

  Baumann, R ^a   Rabaszowski, M ^a   Stenin, I ^a   Tilgner, L ^a   Gaertner Akerboom, M ^a   Scheckenbach, K ^a   Wiltfang, J ^b   Chaker, A ^c,d   Schipper, J ^a   Wagenmann, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Allergic rhinitis; IL 16; IL 33; IL 5; Nasal allergen challenge; Nasal lavage; Nasal secretion; Natural pollen exposure; Soluble ST2

Indexed keywords

CYTOKINE RECEPTOR; INTERLEUKIN 16; INTERLEUKIN 33; INTERLEUKIN 5; ST2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; FEMALE; HUMAN; MALE; NASAL LAVAGE; NOSE SECRETION; POLLEN; POLLEN ALLERGY; POLLINATION; PRIORITY JOURNAL; UPREGULATION;

ALLERGIC RHINITIS; IL-16; IL-33; IL-5; NASAL ALLERGEN CHALLENGE; NASAL LAVAGE; NASAL SECRETION; NATURAL POLLEN EXPOSURE; SOLUBLE ST2;

ADULT; ALLERGENS; FEMALE; HUMANS; INTERLEUKIN-16; INTERLEUKIN-5; INTERLEUKINS; MALE; MIDDLE AGED; NASAL LAVAGE FLUID; RECEPTORS, CELL SURFACE; RHINITIS, ALLERGIC, PERENNIAL; SEASONS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84884692250     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12148     Document Type: Article

References (61)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004; 24:758-64.
2. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001; 108(1 Suppl):S2-8.
3. Nayak AS. The asthma and allergic rhinitis link. Allergy Asthma Proc 2003; 24:395-402.
4. Shaaban R, Zureik M, Soussan D et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372:1049-57.
5. Akdis M, Burgler S, Crameri R et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011; 127:701-21, e1-70.
6. Lingel A, Weiss TM, Niebuhr M et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 2009; 17:1398-410.
7. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179:2551-5.
8. Mjösberg JM, Trifari S, Crellin NK et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12:1055-62.
9. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-90.
10. Palmer G, Lipsky BP, Smithgall MD et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008; 42:358-64.
11. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007; 282:26369-80.
12. Miller AM, Xu D, Asquith DL et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339-46.
13. Verri WA, Guerrero ATG, Fukada SY et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci USA 2008; 105:2723-8.
14. Ober C, Yao T. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev 2011; 242:10-30.
15. Pushparaj PN, Tay HK, H'ng SC et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009; 106:9773-8.
16. Préfontaine D, Lajoie-Kadoch S, Foley S et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183:5094-103.
17. Préfontaine D, Nadigel J, Chouiali F et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010; 125:752-4.
18. Matsuba-Kitamura S, Yoshimoto T, Yasuda K et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol 2010; 22:479-89.
19. Sakashita M, Yoshimoto T, Hirota T et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008; 38:1875-81.
20. Kamekura R, Kojima T, Takano K, Go M, Sawada N, Himi T. The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy 2012; 42:218-28.
21. Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis. Int Arch Allergy Immunol 2012; 158(Suppl 1):47-50.
22. Kim YH, Park C, Lim DH et al. Beneficial effect of anti-interleukin-33 on the murine model of allergic inflammation of the lower airway. J Asthma 2012; 49:738-43.
23. Kim YH, Yang TY, Park C et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012; 67:183-90.
24. Oshikawa K, Kuroiwa K, Tago K et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164:277-81.
25. Sahlander K, Larsson K, Palmberg L. Increased serum levels of soluble ST2 in birch pollen atopics and individuals working in laboratory animal facilities. J Occup Environ Med 2010; 52:214-8.
26. Cruikshank W, Center DM. Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J Immunol 1982; 128:2569-74.
27. Maciaszek JW, Parada NA, Cruikshank WW, Center DM, Kornfeld H, Viglianti GA. IL-16 represses HIV-1 promoter activity. J Immunol 1997; 158:5-8.
28. Cruikshank WW, Center DM, Nisar N et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994; 91:5109-13.
29. Qi JC, Wang J, Mandadi S et al. Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood 2006; 107:135-42.
30. Carriere V, Roussel L, Ortega N et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007; 104:282-7.
31. Wilson KC, Cruikshank WW, Center DM, Zhang Y. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry 2002; 41:14306-12.
32. Akiyama K, Karaki M, Kobayshi R, Dobashi H, Ishida T, Mori N. IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model. Int Arch Allergy Immunol 2009; 149:315-22.
33. Karaki M, Dobashi H, Kobayashi R, Tokuda M, Ishida T, Mori N. Expression of interleukin-16 in allergic rhinitis. Int Arch Allergy Immunol 2005; 138:67-72.
34. Kramer MF, Ostertag P, Pfrogner E, Rasp G. Nasal IL-16 and MIP-1 alpha in late-phase allergic response. Allergy Asthma Proc 2001; 22:127-32.
35. Cruikshank WW, Long A, Tarpy RE et al. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 1995; 13:738-47.
36. de Bie JJ, Jonker EH, Henricks PAJ et al. Exogenous interleukin-16 inhibits antigen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin Exp Allergy 2002; 32:1651-8.
37. McFadden C, Morgan R, Rahangdale S et al. Preferential migration of T regulatory cells induced by IL-16. J Immunol 2007; 179:6439-45.
38. Pinsonneault S, El Bassam S, Mazer B, Cruikshank WW, Laberge S. IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. J Allergy Clin Immunol 2001; 107:477-82.
39. El Bassam S, Pinsonneault S, Kornfeld H, Ren F, Menezes J, Laberge S. Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology 2006; 117:89-96.
40. Trudelle A, El Bassam S, Pinsonneault S, Mazer B, Laberge S. Interleukin-16 inhibits immunoglobulin e production by B lymphocytes. Int Arch Allergy Immunol 2007; 143:109-18.
41. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997; 158:3902-8.
42. McDermott RA, Nelson HS, Dreskin SC. Mediator measurements after daily instillation of allergen: increased IL-5 and decreased IFN-gamma. Allergy Asthma Proc 2008; 29:146-51.
43. Chawes BLK, Edwards MJ, Shamji B et al. A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid. J Allergy Clin Immunol 2010; 125:1387-9, e3.
44. Wagenmann M, Schumacher L, Bachert C. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 2005; 60:1132-8.
45. Riechelmann H, Bachert C, Goldschmidt O et al. Durchführung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege. Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie (Sektion HNO) gemeinsam mit der Arbeitsgemeinschaft Klinische Immunologie [Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology]. Laryngorhinootologie 2003; 82:183-8.
46. Conover WJ. Practical nonparametric statistics. 3rd Edn. New York, NY: Wiley, 1999. 584 p. (Applied probability and statistics section). ISBN: 978-0-471-16068-7.
47. Wang D, Clement P, Smitz J, de Waele M, Derde MP. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995; 106:278-85.
48. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009; 113:1526-34.
49. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008; 121:1484-90.
50. Suzukawa M, Koketsu R, Iikura M et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008; 88:1245-53.
51. Walzl G, Matthews S, Kendall S et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med 2001; 193:785-92.
52. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002; 32:1520-6.
53. Löhning M, Stroehmann A, Coyle AJ et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998; 95:6930-5.
54. Yin H, Li XY, Liu T et al. Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice. Clin Exp Immunol 2012; 170:1-9.
55. Oshikawa K, Yanagisawa K, Tominaga Si, Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002; 299:18-24.
56. Wagenmann M, Baroody FM, Cheng CC, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Bilateral increases in histamine after unilateral nasal allergen challenge. Am J Respir Crit Care Med 1997; 155:426-31.
57. Shimizu M, Matsuda A, Yanagisawa K et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005; 14:2919-27.
58. Calderón MA, Lozewicz S, Prior A, Jordan S, Trigg CJ, Davies RJ. Lymphocyte infiltration and thickness of the nasal mucous membrane in perennial and seasonal allergic rhinitis. J Allergy Clin Immunol 1994; 93:635-43.
59. Lécart S, Lecointe N, Subramaniam A et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002; 32:2979-87.
60. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287:6941-8.
61. Dorman SC, Sehmi R, Gauvreau GM et al. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 2004; 169:565-72.